Xiaowu Dong

Zhejiang Lab — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index4.6kcitations233works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(43), Computational Drug Discovery Methods(30), Ubiquitin and proteasome pathways(30), Synthesis and biological activity(21), Peptidase Inhibition and Analysis(21)

Publications233 total

Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
European Journal of Medicinal Chemistry·2025
Metabolite genetic characterization and bile acid metabolomics reveal deoxycholic acid protective effects on acute pancreatitis
Food Science and Human Wellness·2025Open Access
Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy
Blood·2025Open Access
Novel gsdmd agonist dmb induces synergistic pyroptosis and apoptosis in diffuse large B-cell lymphoma
Blood·2025Open Access
Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma
Blood·2025
SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation
Nature Communications·2025· 1 citedOpen Access
Modular PROTAC/IMiD Bifunctional Molecule Design for the Degradation of Synergistic Targets in the Treatment of Lymphoma
Journal of Medicinal Chemistry·2025· 2 cited
Proton pump inhibitor use and pancreatic risk: evidence from the UK biobank participants and animal experiments
Frontiers in Pharmacology·2025Open Access
Discovery of Piperazine-Amide Derivatives as Highly Potent and Selective RET Inhibitors
ACS Medicinal Chemistry Letters·2025
Development of Dual FLT3 and CHK1 PROTACs for the Treatment of AML
Journal of Medicinal Chemistry·2025· 1 cited
Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma
Journal of Medicinal Chemistry·2025· 2 cited
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
Journal of Medicinal Chemistry·2025· 6 cited
Synergistic adsorption-reduction by ZIF-8 immobilized Ni0 nanoparticles for ultrahigh-capacity uranium extraction from seawater: Integrated experimental and DFT studies
Separation and Purification Technology·2025· 3 cited
Rational engineering of degradation tail-driven CELMoD–antibody conjugates for precision malignancy therapy
Acta Pharmaceutica Sinica B·2025· 1 citedOpen Access
Discovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations
ChemistryOpen·2025Open Access
A Multi-Step Virtual Screening Framework Identifies Novel GPRC5D Inhibitors for Multiple Myeloma Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
Discovery and characterization of sulfonamide derivatives as transcriptional enhanced associate domain (TEAD) inhibitors: a novel approach for targeting hepatocellular carcinoma
Bioorganic Chemistry·2025
Recent advances in functional activatable probes for oncological surgery: Illuminating precision or hindering clinical translation?
European Journal of Medicinal Chemistry·2025
Discovery of Novel c-MET Inhibitors for Hepatocellular Carcinoma Using an Integrated Virtual Screening Approach
ACS Medicinal Chemistry Letters·2025Open Access
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as novel FLT3/IRAK4 inhibitors
European Journal of Medicinal Chemistry·2025· 1 cited
page 1 of 12Next →

Frequent Co-authors

Yongzhou Hu(19), Jinxin Che(14), Qiaojun He(12), Bo Yang(7), Jinhao Zhao(6), Tao Liu(6), Yong Yang(5), Hong Zhu(4), Xin‐Yuan Liu(4), Jingli Cheng(4), Yuxin Zhuang(4), Haiyan Yang(4), Bo Yang(4), Ji Cao(3), Yizhen Jin(3), Liteng Shen(3), Zheyuan Shen(3), Biao Wang(3), Yongjin Xu(3), Tingjun Hou(2)